Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

193.22 +0.41 (+0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Natera to Report its Third Quarter Results on November 6, 2025
From Natera, Inc.
Via Business Wire
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
From Natera, Inc.
Via Business Wire
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
How Do Investors Really Feel About Natera?
 
Via Benzinga
A Glimpse Into The Expert Outlook On Natera Through 8 Analysts
 
Via Benzinga
Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
Why Are Natera (NTRA) Shares Soaring Today
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.2% in the afternoon session after the company announced promising results from its phase 3 IMvigor011 clinical trial for its Signatera... 
Via StockStory
Topics Intellectual Property
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
From Natera, Inc.
Via Business Wire
Natera Named to Fast Company’s Next Big Things in Tech List
From Natera, Inc.
Via Business Wire
Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today
 
Via Benzinga
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
From Natera, Inc.
Via Business Wire
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
From Natera, Inc.
Via Business Wire
2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 That Underwhelm
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Retirement
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
From Natera, Inc.
Via Business Wire
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
From Natera, Inc.
Via Business Wire
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
From Natera, Inc.
Via Business Wire
2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Stocks making big moves yesterday: Acadia Healthcare, Tesla, THOR Industries, Natera, and P10
Check out the companies making headlines yesterday: 
Via StockStory
Topics Electric Vehicles
Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today
 
Via Benzinga
Why Natera (NTRA) Stock Is Down Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.5% in the afternoon session after Wells Fargo & Company initiated coverage on the stock with a neutral "equal weight" rating and set a... 
Via StockStory
Topics Artificial Intelligence Lawsuit
Deep Dive Into Natera Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
If You Invested $100 In Natera Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
2 Unprofitable Stocks on Our Watchlist and 1 We Ignore
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
Why Natera (NTRA) Stock Is Trading Lower Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 2.7% in the afternoon session after the company reached an $8.25 million settlement in a legal case. The case, titled 'Amanda Davis v.... 
Via StockStory
Topics Artificial Intelligence Lawsuit
Why Natera (NTRA) Shares Are Falling Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood... 
Via StockStory
Topics Intellectual Property
3 Reasons We’re Fans of Natera (NTRA)
Since September 2020, the S&P 500 has delivered a total return of 94.8%. But one standout stock has doubled the market - over the past five years, Natera has surged 186% to $176.64 per share. Its... 
Via StockStory
Topics Stocks
1 Cash-Producing Stock to Own for Decades and 2 We Find Risky
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Topics Supply Chain
Why Natera (NTRA) Stock Is Down Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 0.9% in the morning session after the company announced an unfavorable court ruling in its ongoing patent litigation with competitor... 
Via StockStory
Topics Intellectual Property
NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims
NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boosting investor sentiment. 
Via Benzinga
Topics Intellectual Property
Natera Provides Update on Patent Litigation with NeoGenomics
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.